- Dupilumab is associated with improvements in pruritus symptoms in adults and adolescents with atopic dermatitis, according to results from 4 phase 3 clinical trials.
Why this matters
- Pruritus is a major symptom of atopic dermatitis, and these results further support a beneficial role for dupilumab.
- Dupilumab was associated with a greater improvement (least-squares mean percentage change) in daily Peak Pruritus Numerical Rating Scale score compared with placebo (P<.0001 for all style="list-style-type:circle;">
- −47.4% vs −20.5% at 16 weeks in the SOLO 1/2 trials (adult patients, dupilumab 300 mg every 2 weeks or placebo monotherapy).
- −47.9% vs −19.0% at 16 weeks in the AD-ADOL trial (adolescent patients, dupilumab 200 mg baseline weight
- −57.3% vs −30.9% at 52 weeks in the CHRONOS trial (adult patients, dupilumab 300 mg every 2 weeks or placebo with concomitant topical corticosteroids).
- 1505 patients with moderate to severe atopic dermatitis from 4 randomized controlled studies were included.
- Funding: Sanofi; Regeneron Pharmaceuticals, Inc.
- Short duration (16 weeks) of monotherapy trials.